We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interferon-Gamma Release Assays Preferred for Latent TB

By LabMedica International staff writers
Posted on 30 May 2012
Interferon-gamma release assays (IGRAs) are significantly better than tuberculin skin tests (TST) at predicting progression from latent tuberculosis (TB). More...


In order to avoid unnecessary treatment, mass therapy of latent TB infection depends above all on the availability and use of adequate screening tests that more accurately predict progression from latent tuberculosis infection (LTBI) to active tuberculosis than the TST does.

Scientists at the Medical School Hanover (Germany) carried out a meta-analysis to qualitatively evaluate the positive predictive value (PPV) and negative predictive value (NPV) for progression of commercial and “in-house” IGRAs and the TST for persons not receiving preventive treatment. The respective IGRA studies were pooled using both a fixed and a random effect model. In all, 1,225 subjects were tested by "in house" IGRAs, 5,194 by commercial IGRAs and 8,479 by TST.

The pooled PPV for progression for all studies using commercial IGRAs was 2.7%, which was statistically significant compared with 1.5% for the TST.

PPV increased to 6.8% for the IGRAs and 2.4% for the TST when only high-risk groups were considered. Pooled values of NPV for progression for both IGRAs and the TST were very high at 99.7% and 99.4%, although significantly higher for IGRAs.

Five studies included in the metaanalysis utilized “in-house” tests; seven used the T-SPOT.TB ELISPOT (Oxford Immunotec Ltd.; Abingdon, UK); four used the QuantiFERON-TB Gold (QFT-G) and 14 used its successor the QuantiFERON-TB Gold In-Tube (QFT-IT), both products of Cellestis Ltd., (Chadstone, Australia). QFT-IT uses whole blood and produces a result within 16 hours and T-SPOT processes peripheral blood mononuclear cells within eight hours measuring the number of interferon-gamma producing cells.

Roland Diel, MD, MPH, the lead authors of the study said, "This is also highly important for tuberculosis control programs, because a test with a high negative predictive value means that therapy for latent tuberculosis can be limited to test-positive contacts without the danger of overlooking some who are truly infected but undetected by the tests."

The authors concluded that progression rates for commercial IGRA blood tests are remarkably higher than those for the TST, but remain low in absolute numbers. The data suggests that IGRAs provide significant benefits over the TST, but that the use of IGRAs, and testing for LTBI in general, should be targeted at high-risk groups. The study was published online on April 5 2012 in the journal Chest.

Related Links:

Medical School Hanover
Oxford Immunotec Ltd.
Cellestis Ltd.



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.